Targeted drug shows promise for rare Gene-Fueled cancers
NCT ID NCT06383884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called patritumab deruxtecan in adults with advanced solid tumors that have a rare genetic change called an NRG1 fusion. The drug aims to block signals that help these cancers grow. About 30 people will take part to see if the drug can shrink tumors and control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?
- New imaging agent aims to light up hidden tumors
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
- New scan could reveal hidden cancer cells
- New cancer drug DT-9081 tested in early trial – but study stopped early